Therapeutics announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical ...

D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC ...

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) had its price target dropped by stock analysts at Bank of America from $42.00 to $40.00 in a research report issued on Monday ...

4D Molecular Therapeutics announced the enrollment of the first patients in the Phase 3 clinical trial, 4FRONT-1, for its product 4D-150, aimed at treating wet age-related macular degeneration (AMD).

Bank of America Securities analyst Daniel Giraldo maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report) today. The ...

Across the recent three months, 7 analysts have shared their insights on 4D Molecular Therapeutics (NASDAQ:FDMT), expressing a variety of opinions spanning from bullish to bearish. The following ...

Net loss: US$160.9m (loss widened by 60% from FY 2023). US$2.98 loss per share (further deteriorated from US$2.58 loss in FY 2023). Revenue missed analyst estimates by 97%. Earnings per share (EPS ...

Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

Highlights,The New York State Common Retirement Fund adjusted its stake in 4D Molecular Therapeutics, reducing its holdings ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...